76 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
8 May 24
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
(1)
Research and development
Selling, general and administrative
Total operating expenses (2)
Loss from operations
Other income (expense):
Interest … :
Intangible amortization
(2) Amounts include stock-based compensation expense as follows:
Research and development
Selling, general and administrative
Total
NT 10-K
MIRM
Mirum Pharmaceuticals Inc
28 Feb 24
Notice of late annual filing
5:01pm
, partially offset by a $4.2 million decrease in research and development expense
As of December 31, 2023, Mirum had cash and cash equivalents of $286.3
8-K
EX-99.1
xnr460lblx6 h3
28 Feb 24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
zq1z1
2 Nov 23
Results of Operations and Financial Condition
4:06pm
8-K/A
EX-99.4
7nxclbeeku2arx
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.3
jvti142
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.5
7rbili5qz0xttxszs5b
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
yu4qhcf7eq dc
13 Oct 23
Other Events
4:16pm
8-K
EX-10.1
ehomqz0
30 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
ocukiqrgwir2 nn1
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-2.1
ufujvisa
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.1
77cnxd
4 May 23
Results of Operations and Financial Condition
4:02pm